$NGNE
Neurogene Inc. Stock $ngne

$ngne Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000119312515372837 Filed on November 10, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.670M	$1.230M	$1.490M
YoY Change	12.08%	24.24%	115.94%
% of Gross Profit
Research & Development	$3.930M	$3.687M	$6.330M
YoY Change	-37.91%	-30.73%	130.18%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$5.590M	$4.917M	$7.820M
YoY Change	-28.52%	-22.08%	127.33%
Operating Profit
YoY Change
Interest Expense	$20.00K	$4.000K	-$10.00K
YoY Change	-300.0%	100.0%	-80.0%
% of Operating Profit
Other Income/Expense, Net	-$90.00K	-$118.0K	-$260.0K
YoY Change	-65.38%	-553.85%	420.0%
Pretax Income	-$5.660M	-$5.035M	-$8.090M
YoY Change	-30.04%	-19.88%	128.53%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$5.660M	-$5.035M	-$8.090M
YoY Change	-30.04%	-19.88%	128.53%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$327.9K	-$425.7K	-$754.7K
COMMON SHARES
Basic Shares Outstanding	17.21M shares	10.73M shares	10.70M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$74.50M	$117.4M	$39.10M
YoY Change	90.54%	193.5%	183.33%
Cash & Equivalents	$39.53M	$109.4M	$14.91M
Short-Term Investments	$35.00M	$8.000M	$24.20M
Other Short-Term Assets	$300.0K	$500.0K	$100.0K
YoY Change	200.0%	66.67%	-93.33%
Inventory
Prepaid Expenses
Receivables	$0.00	$0.00	$100.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$74.80M	$117.9M	$39.30M
YoY Change	90.32%	192.18%	156.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$89.00K	$81.00K	$105.0K
YoY Change	-15.24%	-16.99%	39.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$38.50M	$0.00	$2.000M
YoY Change	1825.0%	-100.0%
Other Assets	$0.00	$12.00K	$13.00K
YoY Change	-100.0%	-13.44%	-95.31%
Total Long-Term Assets	$38.55M	$93.00K	$2.121M
YoY Change	1717.4%	-98.87%	501.27%
TOTAL ASSETS
Total Short-Term Assets	$74.80M	$117.9M	$39.30M
Total Long-Term Assets	$38.55M	$93.00K	$2.121M
Total Assets	$113.3M	$118.0M	$41.42M
YoY Change	173.63%	142.78%	164.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.800M	$3.900M	$5.200M
YoY Change	-7.69%	-15.22%	766.67%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.792M	$3.859M	$5.203M
YoY Change	-7.9%	-15.59%	98.58%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$131.0K	$100.0K	$72.00K
YoY Change	81.94%	0.0%	741.12%
Total Long-Term Liabilities	$131.0K	$100.0K	$72.00K
YoY Change	81.94%	0.0%	741.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.792M	$3.859M	$5.203M
Total Long-Term Liabilities	$131.0K	$100.0K	$72.00K
Total Liabilities	$4.923M	$4.001M	$5.275M
YoY Change	-6.67%	-13.69%	-29.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$111.3M	-$105.6M	-$89.42M
YoY Change	24.45%	29.87%	36.11%
Common Stock	$0.00	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$108.4M	$114.0M	$36.15M
YoY Change
Total Liabilities & Shareholders Equity	$113.3M	$118.0M	$41.42M
YoY Change	173.63%	142.78%	164.69%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q4
OPERATING ACTIVITIES
Net Income	-$5.660M	-$5.035M	-$8.090M
YoY Change	-30.04%	-19.88%	128.53%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$3.960M	-$4.210M	-$6.700M
YoY Change	-40.9%	0.72%	79.14%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$10.00K	-$20.00K
YoY Change	-50.0%	-50.0%
Acquisitions
YoY Change
Other Investing Activities	-$65.67M	$6.070M	$6.080M
YoY Change	-1180.1%	173.42%	-316.37%
Cash From Investing Activities	-$65.68M	$6.060M	$6.050M
YoY Change	-1185.62%	174.21%	-315.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-150.0K	93.08M	0.000
YoY Change		-186260.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-3.960M	-4.210M	-6.700M
Cash From Investing Activities	-65.68M	6.060M	6.050M
Cash From Financing Activities	-150.0K	93.08M	0.000
Net Change In Cash	-69.79M	94.93M	-650.0K
YoY Change	10636.92%	-4799.5%	-86.32%
FREE CASH FLOW
Cash From Operating Activities	-$3.960M	-$4.210M	-$6.700M
Capital Expenditures	-$10.00K	-$10.00K	-$20.00K
Free Cash Flow	-$3.950M	-$4.200M	-$6.680M
YoY Change	-40.87%	0.96%	78.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q3	us-gaap	Assets Assets	118028000
CY2015Q3	us-gaap	Cash Cash	92980000
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17211986	shares
CY2014Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2982000
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15869000
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	858957	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.72
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17211986	shares
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000001
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	152802	shares
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17211986	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.29
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.000001
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	114027000
CY2015Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	219637000
CY2015Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	142000
CY2015Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3859000
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-105613000
CY2015Q3	us-gaap	Liabilities Liabilities	4001000
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	118028000
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	0
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3859000
CY2015Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3000
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2231000
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12000
CY2015Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3513000
CY2015Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	19000
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	81000
CY2015Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	8038000
CY2015Q3	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	0
CY2015Q3	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	7896000
CY2015Q3	us-gaap	Assets Current AssetsCurrent	117935000
CY2015Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	16393000
CY2015Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	8038000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	824604	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.79
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10695108	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000001
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10695108	shares
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	36147000
CY2014Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	24191000
CY2014Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	2003000
CY2015Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	0
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	125567000
CY2014Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	26122000
CY2014Q4	us-gaap	Assets Current AssetsCurrent	39301000
CY2014Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	6555000
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	24191000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14906000
CY2015Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109373000
CY2015Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	8035000
CY2015Q3	aqxp	Prepayments And Deposits Current PrepaymentsAndDepositsCurrent	505000
CY2015Q3	aqxp	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue	3736000
CY2015Q3	aqxp	Stock Shares Authorized Net StockSharesAuthorizedNet	55000000	shares
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11006000
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	24195000
CY2014Q4	aqxp	Prepayments And Deposits Current PrepaymentsAndDepositsCurrent	139000
CY2014Q4	aqxp	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	2003000
CY2014Q4	aqxp	Available For Sale Securities Debt Maturities After One Through Two Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost	2003000
CY2014Q4	aqxp	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue	789000
CY2014Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	72000
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5203000
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-89416000
CY2014Q4	us-gaap	Liabilities Liabilities	5275000
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	41422000
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	0
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5203000
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4000
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13000
CY2014Q4	us-gaap	Assets Assets	41422000
CY2014Q4	us-gaap	Cash Cash	8351000
CY2014Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	65000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	105000
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	958000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	125000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5251000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1380000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	7000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15930000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15937000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10792000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0167	pure
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.97
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8247212	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.08	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.33
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7984052	shares
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M13D
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	86000
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	48000
	us-gaap	Net Income Loss NetIncomeLoss	-15937000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15731000
	us-gaap	Repayments Of Debt RepaymentsOfDebt	2600000
	us-gaap	Interest Paid InterestPaid	32000
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	36474000
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-218000
	us-gaap	Share Based Compensation ShareBasedCompensation	585000
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	20000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4863000
	us-gaap	Operating Expenses OperatingExpenses	14557000
	us-gaap	Interest Expense InterestExpense	459000
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	186000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-29624000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	45279000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11754000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	16000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2983000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	585000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2803000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	320000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	6920000
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	53130000
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	80000
	aqxp	Fee And Penalty On Bank Loan Repayment FeeAndPenaltyOnBankLoanRepayment	100000
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	aqxp	Amortization Of Preferred Stock Discount AmortizationOfPreferredStockDiscount	1884000
	aqxp	Share Issuance Expenditures Incurred But Not Yet Paid ShareIssuanceExpendituresIncurredButNotYetPaid	50000
	aqxp	Adjustments For Temporary Equity Accretion Liquidation Preference AdjustmentsForTemporaryEquityAccretionLiquidationPreference	1133000
	aqxp	Income Tax Expense On Preferred Stock IncomeTaxExpenseOnPreferredStock	100000
	aqxp	Reversal Of Income Tax Payable On Preferred Stock ReversalOfIncomeTaxPayableOnPreferredStock	1898000
	aqxp	Extinguishment Of Remaining Share Issuance Costs Due To Conversion Of Preferred Stock ExtinguishmentOfRemainingShareIssuanceCostsDueToConversionOfPreferredStock	439000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>1. Nature of operations</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Aquinox Pharmaceuticals, Inc. and its wholly owned subsidiary, Aquinox Pharmaceuticals (Canada) Inc., (consolidated, the “Company”) is a clinical stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting SHIP1 (SH2-containing inositol-5’-phosphatase 1), which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Aquinox Pharmaceuticals, Inc. was originally incorporated under the name of Aquinox Pharmaceuticals (USA) Inc. on May 31, 2007 in the State of Delaware, United States. On January 27, 2014, Aquinox Pharmaceuticals (USA) Inc. changed its name to Aquinox Pharmaceuticals, Inc. (“Aquinox USA”).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Aquinox Pharmaceuticals (Canada) Inc. (“AQXP Canada”) was originally incorporated under the name of 6175813 Canada Inc. on December 26, 2003 under the Canada Business Corporations Act. In May 2014, after a corporate restructuring, the name was changed to Aquinox Pharmaceuticals (Canada) Inc.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The Company operates in Vancouver, British Columbia, Canada.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16776000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	12170	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y4M24D
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0148	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	49349	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>(b) Use of estimates and assumptions</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring management estimates are the valuation of stock options and warrants, amortization and depreciation, accrual of expenses, valuation allowance for deferred income taxes, and contingencies. Actual results could differ from those estimates.</p> </div>
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	191878	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.58
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.46
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	870320	shares
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001404644
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M13D
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	9.26
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.98	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.46
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Registrant Name EntityRegistrantName	AQUINOX PHARMACEUTICALS, INC
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.99
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.02
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	18147000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	93096000
	us-gaap	Share Based Compensation ShareBasedCompensation	1145000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	94467000
	dei	Trading Symbol TradingSymbol	AQXP
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11096369	shares
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M4D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	287750	shares
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16000
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-46000
	us-gaap	Net Income Loss NetIncomeLoss	-16197000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16197000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	364000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	6063000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-365000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-450000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	7000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16190000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16197000
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-70000
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-39000
	us-gaap	Operating Expenses OperatingExpenses	15747000
	us-gaap	Interest Expense InterestExpense	15000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11873000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1515000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1121000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1145000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3874000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	18163000
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	98038000
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	36000
	aqxp	Share Issuance Expenditures Incurred But Not Yet Paid ShareIssuanceExpendituresIncurredButNotYetPaid	169000
	aqxp	Period Shares Reserved For Issuance Will Increase PeriodSharesReservedForIssuanceWillIncrease	P10Y
	aqxp	Fair Value Transfers Between Level One Level Two And Level Three Amount FairValueTransfersBetweenLevelOneLevelTwoAndLevelThreeAmount	0
	aqxp	Common Stock Reserved For Issuance Description CommonStockReservedForIssuanceDescription	Additionally, the number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1 of each year for a period of up to 10 years, beginning on January 1, 2015 and ending on and including January 1, 2024, by 4% of the total number of shares of capital outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the board of directors.
	aqxp	Stock Based Compensation Increase In Common Stock Issuance Percentage StockBasedCompensationIncreaseInCommonStockIssuancePercentage	0.04	pure
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M28D
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0170	pure
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	824721	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.08	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.16
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10695042	shares
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-6284000
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6284000
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	26000
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6000
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6278000
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6284000
CY2014Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	29000
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	6310000
CY2014Q3	us-gaap	Interest Expense InterestExpense	2000
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5323000
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	233000
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	987000
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	870320	shares
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11841147	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-5035000
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5035000
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-38000
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-118000
CY2015Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5036000
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5035000
CY2015Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-76000
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	4917000
CY2015Q3	us-gaap	Interest Expense InterestExpense	4000
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3687000
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	424000
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1230000
CY2015Q3	aqxp	Fair Value Transfers Between Level One Level Two And Level Three Amount FairValueTransfersBetweenLevelOneLevelTwoAndLevelThreeAmount	0

Files In Submission

Name	View Source	Status
0001193125-15-372837-index-headers.html	Edgar Link	pending
0001193125-15-372837-index.html	Edgar Link	pending
0001193125-15-372837.txt	Edgar Link	pending
0001193125-15-372837-xbrl.zip	Edgar Link	pending
aqxp-20150930.xml	Edgar Link	completed
aqxp-20150930.xsd	Edgar Link	pending
aqxp-20150930_cal.xml	Edgar Link	unprocessable
aqxp-20150930_def.xml	Edgar Link	unprocessable
aqxp-20150930_lab.xml	Edgar Link	unprocessable
aqxp-20150930_pre.xml	Edgar Link	unprocessable
d35814d10q.htm	Edgar Link	pending
d35814dex311.htm	Edgar Link	pending
d35814dex312.htm	Edgar Link	pending
d35814dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NGNE
Neurogene Inc. Stock $ngne

2015 Q4 Form 10-Q Financial Statement

#000119312515372837 Filed on November 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NGNE Neurogene Inc. Stock $ngne

2015 Q4 Form 10-Q Financial Statement

#000119312515372837 Filed on November 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NGNE
Neurogene Inc. Stock $ngne